Project Grant R01HL171992
Award Date
9/1/24
Completion Date
6/30/28
Dollars Obligated
$807K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $777,258 to the Beth Israel Deaconess Medical Center, Inc. (Bidmc) to conduct research aimed at improving the understanding and treatment of heart failure in patients with hypertrophic cardiomyopathy (HCM). The key objectives of this research project are to use advanced cardiac imaging techniques, such as cardiac magnetic resonance...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $771,750 to the University of California, Los Angeles (UCLA) to investigate the role of macrophages in regulating cardiac muscle metabolism following myocardial infarction. The 4-year project aims to shed novel insight into how macrophages recruited to the infarcted heart disrupt cardiac muscle metabolism and energetics, with the goal...
The federal Project Grant award K08HL179262, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research led by Dr. Joshua Meisner at the University of Michigan to elucidate the mechanical and metabolic pathways underlying MYBPC3-related hypertrophic cardiomyopathy (HCM). The $167,400 award, granted on May 15, 2025, aims to establish mouse and induced pluripotent stem cell models of severe, adolescent-onset...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $748,829 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the Texas A&M University System Health Science Center (TAMU HSC) to investigate the metabolic resuscitation system and its connection to the pathogenesis of heart failure. The overarching objective is to determine how a compromised metabolic resuscitation system contributes to the progression of heart failure, with the goal of identifying novel...
The University of Arizona was awarded a $1,309,340.00 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on disruption of the cardiac-coronary axis as a mechanism of heart failure with preserved ejection fraction (HFpEF). The 4-year grant, beginning on July 1, 2024 and ending on May 31, 2028, will support an interdisciplinary research approach encompassing molecular, cellular, vascular...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $750,406 to the University of Cincinnati to develop novel 4D parametric image reconstruction techniques for dynamic 82Rb PET myocardial perfusion imaging. The goal is to significantly reduce measurement uncertainty and improve the diagnostic accuracy and reliability of this imaging approach for evaluating ischemic heart disease...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $756,895 to Duke University to develop, validate, and determine the clinical utility of a precision genetic testing approach guided by machine learning (ML) algorithms. The objective is to enhance the diagnosis of hypertrophic cardiomyopathy (HCM) and transthyretin amyloidosis (ATTR-CM), which are rare but common in aggregate, through the integration of ML-based...
This Project Grant award in the amount of $699,133 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to advance the understanding of heart failure with preserved ejection fraction (HFPEF), a condition affecting approximately 3 million Americans. The research will map the epigenomic and transcriptomic regulatory landscape across multiple organs, including the heart, kidney, and liver, to investigate the molecular...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $618,045 to the University of Arizona to conduct research on identifying new mechanisms and targets for treating early onset diastolic dysfunction in hypertrophic cardiomyopathy (HCM). The research aims to fully characterize three specific functional domains of the cardiac thin filament linked to the regulation of relaxation, determine...
The University of California, Santa Barbara (UCSB) was awarded a $194,375 Project Grant (R21HL173827) by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The objective of this 2-year research project is to determine how extracellular matrix (ECM) remodeling during cardiomyopathy alters myocardial (heart tissue) viscoelasticity and the extent to which those mechanical changes can drive disease progression. The...